Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) and Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced that earlier today the shareholders of both companies approved the merger of the two...
InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that Institutional Shareholder Services (ISS), the nation's leading independent proxy advisory firm, has recommended that...
InKine Pharmaceutical Company, Inc. (Nasdaq: INKP): ? Highlights ? -- Entered into a definitive merger agreement with Salix Pharmaceuticals, Ltd. ? -- Filed New Drug Application (NDA) for...
InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that seven abstracts with data from clinical studies of the Company's next-generation purgative product, INKP-102, have...
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and InKine Pharmaceutical Company, Inc. (NASDAQ: INKP) announced today that the two companies have entered into a definitive merger agreement under which...
InKine Pharmaceutical Company, Inc. (Nasdaq:INKP) today announced that the Philadelphia Court of Common Pleas entered a final judgment order approving the settlement of InKine's class...
InKine Pharmaceutical Company, Inc. (NASDAQ:INKP): -Highlights- ? -- Completed Phase III Clinical Study and Submitted a New Drug Application to FDA for Approval of INKP-102 ? -- Grew...
InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that on April 29, 2005 the Company submitted an electronic New Drug Application (NDA) for the United States marketing approval...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
